IN8BIO, INC.

Clinical-stage biopharma developing gamma-delta T cell therapies for solid & hematological tumors.

INAB | US

Overview

Corporate Details

ISIN(s):: US45674E1091
LEI:
Country:: United States of America
Address:: EMPIRE STATE BUILDING, 10118 NEW YORK
Website:: https://www.in8bio.com
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

IN8BIO, INC. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell therapies for solid and hematological tumors. The company's proprietary DeltEx™ platform employs allogeneic, autologous, iPSC, and genetically modified approaches to develop novel cell therapies. A pioneer in the field, IN8BIO was the first company to advance genetically modified gamma-delta T cells into clinical trials. Its lead product candidates include INB-400 (Phase 2 for glioblastoma), INB-200 (Phase 1 for glioblastoma), and INB-100 (Phase 1 for leukemia), complemented by a portfolio of preclinical programs. The company's stated mission is to achieve "CANCER ZERO" by developing next-generation treatments for cancer patients.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all IN8BIO, INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for IN8BIO, INC.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for IN8BIO, INC. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Mabion S.A. Global CDMO providing end-to-end services for developing and manufacturing complex biologic drugs.	Poland	MAB
MACROGENICS INC Biopharma firm developing innovative antibody-based therapeutics for cancer treatment.	United States of America	MGNX
MADRIGAL PHARMACEUTICALS, INC. Develops and delivers the first FDA-approved treatment for the liver disease MASH.	United States of America	MDGL
Magle Chemoswed Holding AB A CDMO for pharma/med device firms, offering end-to-end development and specialized manufacturing.	Sweden	MAGLE
Mainz BioMed N.V. Develops at-home diagnostic tests for the early detection of life-threatening cancers.	Germany	MYNZ
MANNKIND CORP Develops inhaled therapies for endocrine, orphan lung, and cardiometabolic diseases.	United States of America	MNKD
MARAVAI LIFESCIENCES HOLDINGS, INC. Provides nucleic acid products and biologics safety testing for new therapies and vaccines.	United States of America	MRVI
Marinomed Biotech AG Develops virus-blocking products & immunology therapies via proprietary technology platforms.	Austria	MARI
Marker Therapeutics, Inc. Developing non-genetically modified T cell immunotherapies for hematologic and solid tumors.	United States of America	MRKR
Matinas BioPharma Holdings, Inc. Developing oral drugs via a lipid nano-crystal platform for infections, oncology & inflammation.	United States of America	MTNB